Switching strategies for antipsychotic monotherapy in schizophrenia: a multi-center cohort study of aripiprazole

被引:0
作者
Yoshiaki Obayashi
Satoshi Mitsui
Shinji Sakamoto
Nozomu Minao
Bunta Yoshimura
Toshiki Kono
Yuji Yada
Yuko Okahisa
Soshi Takao
Yoshiki Kishi
Toshihiko Takeda
Manabu Takaki
Norihito Yamada
机构
[1] Okayama University Graduate School of Medicine,Department of Neuropsychiatry
[2] Dentistry and Pharmaceutical Sciences,Department of Psychiatry
[3] Okayama Psychiatric Medical Center,Department of Psychiatry
[4] Zikei Hospital,Department of Psychiatry
[5] Fukuyama Kokorono Hospital,Department of Epidemiology
[6] Okayama University Graduate School of Medicine,undefined
[7] Dentistry and Pharmaceutical Sciences,undefined
来源
Psychopharmacology | 2020年 / 237卷
关键词
Aripiprazole; Switching; Monotherapy; Chronic schizophrenia; Cox proportional hazards model;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:167 / 175
页数:8
相关论文
共 245 条
[1]  
Burris KD(2002)Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors J Pharmacol Exp Ther 302 381-389
[2]  
Molski TF(2007)The clinical global impressions scale: applying a research tool in clinical practice Psychiatry (Edgmont) 4 28-37
[3]  
Xu C(2009)Quality of life in caregivers of patients with schizophrenia: a literature review Health Qual Life Outcomes 7 84-399
[4]  
Ryan E(2003)Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study Psychopharmacology 166 391-572
[5]  
Tottori K(2013)Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations CNS Drugs 27 545-1203
[6]  
Kikuchi T(2018)Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease Study 2016 Schizophr Bull 44 1195-995
[7]  
Yocca FD(2008)Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study Am J Psychiatry 165 988-318
[8]  
Molinoff PB(2018)The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses Ther Adv Psychopharmacol 8 303-743
[9]  
Busner J(2007)Unique pharmacological profile of aripiprazole as the phasic component buster Psychopharmacology 191 741-90
[10]  
Targum SD(2010)Suicide and schizophrenia: a systematic review of rates and risk factors J Psychopharmacol 24 81-644